Skip to main content
. Author manuscript; available in PMC: 2013 Jul 18.
Published in final edited form as: Clin Cancer Res. 2012 Apr 11;18(11):3163–3169. doi: 10.1158/1078-0432.CCR-11-3090

Figure 2.

Figure 2

Pharmacodynamic biomarker assessment. NSE and CYFRA thresholds define a patient population with markedly poorer prognosis as assessed by PFS (A) and OS(B). Patients with high plasma pro-GRP (correlating with BCL2 gene amplification) showed increased apoptosis as assessed by the M30 ELISA assay (C) and did not show an increase in CTC from baseline to day 14, in contrast to patients with low plasma pro-GRP(D).